Adial Pharmaceuticals (ADIL) Convertible Debt (2017 - 2018)
Adial Pharmaceuticals (ADIL) posted Convertible Debt of $132854.0 for Q2 2018, little changed sequentially from $132854.0 in Q4 2017.
Adial Pharmaceuticals (ADIL) Convertible Debt (2017 - 2018) Analysis & Trends
Adial Pharmaceuticals has reported Convertible Debt for 2 years, with the latest figure at $132854.0 in Q2 2018.
- Quarterly Convertible Debt changed N/A year-over-year to $132854.0 in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $132854.0 (changed N/A YoY) and the FY2017 annual result came in at $132854.0, changed N/A from the prior year.
- Convertible Debt held at $132854.0 in Q2 2018 per ADIL's latest filing, from $132854.0 in the prior quarter.
- Over five years, Convertible Debt peaked at $132854.0 in Q4 2017 and troughed at $132854.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Adial Pharmaceuticals | 27.27 Mn | 27.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 132,854.00 |
| Dec 31, 2017 | 132,854.00 |